Estrogen Receptor Alpha and its Ubiquitination in Breast Cancer Cells.
Estrogen receptor alpha
breast cancer
endocrine therapy
monoubiquitination
non-covalent ubiquitin binding
polyubiquitination.
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
09
2018
revised:
09
10
2018
accepted:
09
10
2018
pubmed:
17
10
2018
medline:
22
7
2020
entrez:
17
10
2018
Statut:
ppublish
Résumé
More than 70% of all breast cancer cases are estrogen receptor alpha-positive (ERα). ERα is a member of the nuclear receptor family, and its activity is implicated in the gene transcription linked to the proliferation of breast cancer cells, as well as in extranuclear signaling pathways related to the development of resistance to endocrine therapy. Protein-protein interactions and posttranslational modifications of ERα underlie critical mechanisms that modulate its activity. In this review, the relationship between ERα and ubiquitin protein (Ub), was investigated in the context of breast cancer cells. Interestingly, Ub can bind covalently or non-covalently to ERα resulting in either a proteolytic or non-proteolytic fate for this receptor. Thereby, Ub-dependent molecular pathways that modulate ERα signaling may play a central role in breast cancer progression, and consequently, present critical targets for treatment of this disease.
Identifiants
pubmed: 30324876
pii: CDT-EPUB-93665
doi: 10.2174/1389450119666181015114041
doi:
Substances chimiques
ESR1 protein, human
0
Estrogen Receptor alpha
0
Ubiquitin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
690-704Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.